^
    Back
    Association details:
    Biomarker:NEAT1 overexpression
    Cancer:Glioblastoma
    Drug Class:PD-L1 inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Clin Cancer Res
    Title:

    Clinical Importance of the lncRNA NEAT1 in Cancer Patients Treated with Immune Checkpoint Inhibitors

    Published date:
    06/13/2023
    Excerpt:
    We identified the lncRNA NEAT1 as commonly upregulated between patients with melanoma with complete therapeutic response and patients with GBM with longer survival following anti-PD-1/PD-L1 treatment.
    DOI:
    10.1158/1078-0432.CCR-22-3714